Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Mike Putman EBRheum
3 years 1 month ago
Another poster from my research group!
Investigated recommendations in ACR/EULAR guidelines
<1/6th informed by head 2 head RCT
We need more comparative effectivness research!
#ACR22 @RheumNow #1284 https://t.co/HQoeKj0cxy
Richard Conway RichardPAConway
3 years 1 month ago
Moura et al. 22 case series of VEXAS. Lung involvement common, Symptoms in 95%. HRCT abnormal 73%. PFTs abnormal 20%. Changes non specific inflammatory parenchymal, steroid responsive. @RheumNow #ACR22 Abstr#1569 https://t.co/E6vUnvxSdQ https://t.co/l4aEmpy8OX
Richard Conway RichardPAConway
3 years 1 month ago
Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about this. We should drink more sake it seems! @RheumNow #ACR22 Abstr#1206 https://t.co/En5pSMUNp7 https://t.co/c67r9fsHJT
Mike Putman EBRheum
3 years 1 month ago
Exciting trial for PMR, SAPHYR RCT of sarilumab (IL6) in relapsing/refractory PMR
I interviewed Robert Speira aobut the trial for @RheumNow, arriving to your podcast inbox!
Overall very exciting, need options for this group and nice to see PMR getting attention
#ACR22 #ACRBest https://t.co/nPurVhpNws
Richard Conway RichardPAConway
3 years 1 month ago
Johnson et al. Increased risk of heart failure and heart failure mortality in RA. No improvement over time. @RheumNow #ACR22 Abstr#1204 https://t.co/MGEgmORGuL https://t.co/9zDYjZiCh1
Richard Conway RichardPAConway
3 years 1 month ago
Ferrada @maferradastrong et al. HSCT in VEXAS. 20 evaluated. Indications refractory disease or haematologic abnormalities. Completed in 2, ongoing in 2. @RheumNow #ACR22 Abstr#1568 https://t.co/01SeHQcIsh https://t.co/XCgz4cTQCJ
Janet Pope Janetbirdope
3 years 1 month ago
What to do? Should you cycle TNFi in PsA and SpA or move on? 86 Pts from CorEvitas w PsA or Ankylosing spondylitis. TNF switching was not a home run - at 6 mo on 2nd TNF only 15% were in low disease activity. 21% persistence at 2 yrs. Use another Rx! Abst#1499 #ACR22 @rheumnow
Catherine Sims, MD DrCassySims
3 years 1 month ago
Inflammation causing HTN in AS?
Abstract #0384 #ACR22 @RheumNow
🫀413 patients followed for median 12 years
🫀14% developed HTN
🫀Baseline disease duration was an independent RF for HTN
🫀ESR > 20 sig. associated with HTN
Richard Conway RichardPAConway
3 years 1 month ago
Martín-Varillas et al. ADA vs certolizumab in Cystoid Macular Edema in Behcets. "Equally" effective here but 80% of the certolizumab patients were previously refractory to ADA. @RheumNow #ACR22 Abstr#1567 https://t.co/ZKr38i2iA5 https://t.co/Jbtqlv9YAF
Richard Conway RichardPAConway
3 years 1 month ago
Kayadibi et al. Venous halo sign in Behcets. 86% of Behcets thrombophlebitis vs 13% non-Behcets @RheumNow #ACR22 Abstr#1251 https://t.co/fnSDYhaFa0 https://t.co/luIZH9SHwW
Eric Dein ericdeinmd
3 years 1 month ago
Ab1011 #ACR22
@SMerjanah: Fracture rates among vets with AS
Increasing fx incidence for AS and comparator groups over time
There was increase in fractures during TNFi era 2004-2021 compared to pre-TNFi, does not show fx sparing effect
@RheumNow https://t.co/fTSYbFcxqo
Richard Conway RichardPAConway
3 years 1 month ago
Wiebe et al. Steroids <=5mg/day not associated negative effect on BMD. Of course steroid-related increase in fracture risk is not fully captured by BMD effect @RheumNow #ACR22 Abstr#1318 https://t.co/Ond5gzopRa https://t.co/HX2AUyQmsf
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#1569 Lung complications are common in #VEXAS but what are the common radiologic findings? A cohort study in 22 men showed abnormalities were found in most patients but were non-specific. Most commonly parenchymal changes (73%) @RheumNow https://t.co/kjYSHON2yN
Richard Conway RichardPAConway
3 years 1 month ago
Carter et al. Case series showing rapid effect of anifrolumab in refractory discoid lupus and SCLE. @RheumNow #ACR22 Abstr#0974 https://t.co/RjnNxjGJoP…
Richard Conway RichardPAConway
3 years 1 month ago
Pala et al. Increasing disease activity by CDAI associated increasing patient-reported cognitive dysfunction in RA. More pronounced in younger patients. @RheumNow #ACR22 Abstr#1397 https://t.co/eRFxe27qgq https://t.co/NUtTaAcrik
Poster Hall